KINDERHOOK, N.Y.--(BUSINESS WIRE)--May 31, 2006--American Bio Medica Corporation (NASDAQ: ABMC - News) today announced that the US Food and Drug Administration (FDA) has granted the Company 510(k) clearance on its Rapid TOX, a cost effective drug screen in a horizontal cassette platform that simultaneously detects two to ten drugs of abuse in a urine specimen. The clearance allows ABMC to provide the Rapid TOX to customers in clinical markets.
ABMC Chief Executive Officer Stan Cipkowski stated, “Rapid TOX has opened up a lot of doors for us in the workplace and occupational health markets and has helped us to provide another cost effective drug test to the criminal justice market. This FDA clearance will now allow us to complete a relationship with a global partner and offer hospitals and physicians an alternative product for use in emergency rooms and patient drug testing programs.”
Rapid TOX can be used by pipetting, or dropping, a urine specimen into a channel in the cassette, or the cassette can be dipped into a urine specimen. Rapid TOX can also be used with the Company’s Rapid Reader(TM); the first FDA-cleared all inclusive drug screen result interpretation and data management system.
For more information on ABMC or its drug testing products, please visit www.abmc.com.
About American Bio Medica Corporation
American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world’s most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC’s Rapid Drug Screen®, Rapid One®, Rapid TEC®, RDS® InCup® and Rapid TOX(TM) products test for the presence or absence of drugs of abuse in urine, while OralStat® tests for the presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid Reader(TM) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.
This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company’s products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company’s dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled “Risk Factors” in the Company’s annual report on Form 10-KSB for the fiscal year ended December 31, 2005, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company’s common shares.
Contact: American Bio Medica Corporation Stan Cipkowski, 800-227-1243, ext. 106 or BPC Financial Marketing: John Baldissera, 800-368-1217
Source: American Bio Medica Corporation
